Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
